Exercise-Induced Rates of Fat Oxidation with and Without Ingestion of a Caffeine-Based Energy Drink (EDX)
A Crossover Study to Examine Exercise-Induced Rates of Fat Oxidation with and Without Ingestion of a Caffeine-Based Energy Drink
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Charles, Missouri, United States, 63301
- Exercise and Performance Nutrition Laboratory
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female participants between 18 - 50 years of age
- Signed informed consent
- Healthy defined as currently not being treated for an active cardiac, pulmonary, metabolic, immunological, neurological, respiratory, orthopedic, musculoskeletal, psychiatric, or reproductive disease or disorder. With the research team and principal investigator's discretion, some ongoing treatments will be permitted if a determination is made that the treatment will not increase the risk of study participation and the treatment will not confound with desired study outcomes
- Physically active which is defined as performing aerobic or resistance-based physical exercise between 2 and 5 times per week
- Moderate caffeine users (~300 mg/day)
- Body mass index values will range from >24.0 to < 31.9 kg/m2. The average body mass index for the entire study cohort will be less than 31.99 kg/m2. As such, an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 31.99 kg/m2
- Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures
Exclusion Criteria:
- Body mass index > 31.9 kg/m2
- Positive medical history and/or is currently being treated for some form of heart or cardiovascular, neurological impairment, disease or condition, immune disorder or disease, thyroid disease, kidney disease, renal failure, regular dialysis, liver disease, or other diagnosed hepatic impairment
- Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose > 126 mg/dL)
- Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year
- History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).
- Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)
- Currently prescribed statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha-blockers, Vasodilators, etc.) or any other medication at the discretion of the principal investigator
- Current smoker (>10 cigarettes per day)
- Participants who are lactating, pregnant, or planning to become pregnant
- History of alcohol or substance abuse in the 6 months prior to screening
- Receipt or use of an investigational product in another research study within 60 days of beginning the study protocol
- Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data
- Extensive travel (>1 month) that will disrupt the original outline of the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Caffeine-Based Energy Drink
12 oz Caffeine-based energy drink providing 200 mg caffeine
|
Energy drink with 200 mg caffeine
|
|
Placebo Comparator: Placebo
12 oz placebo void of all active ingredients
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of a caffeine-based energy drink ingestion on fat oxidation rates during exercise.
Time Frame: 150 minutes during exercise
|
Fat oxidation rate (grams/min) during exercise
|
150 minutes during exercise
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of a caffeine-based energy drink ingestion on energy expenditure rates during exercise.
Time Frame: 150 minutes during exercise
|
Energy expenditure (kcals/min)
|
150 minutes during exercise
|
|
Impact of a caffeine-based energy drink ingestion on carbohydrate oxidation during exercise
Time Frame: 150 minutes during exercise
|
Carbohydrate oxidation rates (grams/min)
|
150 minutes during exercise
|
|
Impact of a caffeine-based energy drink ingestion on plasma glycerol concentration
Time Frame: 150 minutes after intervention ingestion
|
Plasma glycerol concentration
|
150 minutes after intervention ingestion
|
|
Impact of a caffeine-based energy drink ingestion on plasma free fatty acid concentration
Time Frame: 150 minutes after intervention ingestion
|
Plasma free fatty acid concentration
|
150 minutes after intervention ingestion
|
|
Impact of a caffeine-based energy drink ingestion on ratings of perceived exertion
Time Frame: 150 minutes after intervention ingestion
|
Rating of Perceived Exertion (RPE) scale
|
150 minutes after intervention ingestion
|
|
Impact of a caffeine-based energy drink ingestion on exercise performance
Time Frame: 150 minutes after intervention ingestion
|
Cycling time trial
|
150 minutes after intervention ingestion
|
|
Impact of a caffeine-based energy drink ingestion on reaction time
Time Frame: 150 minutes after intervention ingestion
|
Simple/ choice reaction time
|
150 minutes after intervention ingestion
|
|
Impact of a caffeine-based energy drink ingestion on trail making test performance
Time Frame: 150 minutes after intervention ingestion
|
Trail making test
|
150 minutes after intervention ingestion
|
|
Impact of a caffeine-based energy drink ingestion on Cognition
Time Frame: 150 minutes after intervention ingestion
|
Serial 7 Cognitive processing test
|
150 minutes after intervention ingestion
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of a caffeine-based energy drink ingestion on adverse events
Time Frame: 3 weeks
|
Self-reported adverse events
|
3 weeks
|
|
Impact of a caffeine-based energy drink ingestion on heart rate
Time Frame: 3 weeks
|
Heart rate (bpm)
|
3 weeks
|
|
Impact of a caffeine-based energy drink ingestion on blood pressure
Time Frame: 3 weeks
|
Blood Pressure (mmHg)
|
3 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 23-26
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.